Back to search results

Topical Capsaicin for Chemotherapy-Induced Peripheral Neuropathy Pain

This study is exploring if a topical patch called Qutenza (capsaicin) can help reduce pain from chemotherapy-induced peripheral neuropathy (CIPN) and improve walking. CIPN is nerve damage caused by chemotherapy, leading to pain. Researchers want to see how safe Qutenza is and if it helps with pain intensity and how people walk. You might be able to join if you are at least 18 years old, have chronic CIPN pain in your legs (lasting over 90 days) from certain chemotherapy drugs, and your pain is rated 4 or higher on a 0-10 scale. You must have finished chemotherapy within the last year and be seen at MD Anderson Cancer Center. The study aims to enroll 20 participants.

Study design
This is a single-center pilot study, meaning it's a small, initial study at one location. It is an interventional study, but the phase is not specified.
What's involved
The study will assess changes in your walking, pain intensity, and sensation before and after using topical capsaicin. Some optional tests include skin biopsies.
Compensation
Not stated in the trial record.
Follow-up
Your safety and side effects will be monitored throughout the study, for an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06744816

Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study

Recruiting
EARLY_PHASE1Ages 18+InterventionalSupportive care
M.D. Anderson Cancer Center
~20 participants
Updated 2026-06-26 on ClinicalTrials.gov
What's tested:Qutenza Patch

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and adverse events (AE)s
Measured over Through study completion; an average of 1 year

Conditions

Peripheral Neuropathy Due to Chemotherapy

Explore related trials

Peripheral Neuropathy

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Saba Javed, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Saba Javed, MD
[email protected]
713-792-9530
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants diagnosed with pain of the lower extremity from chronic (\>90 days duration) CIPN (due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds), seen at MD Anderson Cancer Center
Participants reporting baseline pain ≥ 4 (0-10 scale, NRS)
Participants age 18+
Participants who have completed chemotherapy within the last year at the time of enrollment.

Exclusion

Participants with cognitive dysfunction
Participants with recent history (\<6 months) of drug or alcohol abuse
Participants with open skin lesion or undergoing antibiotic therapy for local for systemic infection
Participants with allergies to capsaicin or adhesives
Pregnant participants

What this trial measures

  • Safety and adverse events (AE)sThrough study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0